Canada - English - Health Canada

aventis pasteur limited - diphtheria toxoid - liquid - 0.2lf - diphtheria toxoid 0.2lf - diphtheria

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sm pharmaceuticals sdn. bhd. - tetanus toxoid -

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37), bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (unii: 8c367iy4ey) (bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) - unii:8c367iy4ey), bordetella pertussis pertactin antigen (unii: 63gd90pp8x) (bordetella pertussis pertactin antigen - unii:63gd90pp8x), bordetella pertussis fimbriae 2/3 antigen (unii: 1o0600285a) (bordetella pertussis fimbriae 2/3 antigen - unii:1o0600285a), poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - pentacel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to haemophilus influenzae type b. pentacel is approved for use as a four dose series in children 6 weeks through 4 years of age (prior to fifth birthday). a severe allergic reaction (eg, anaphylaxis) after a previous dose of pentacel or any other diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine, inactivated poliovirus vaccine or h. influenzae type b vaccine, or any ingredient of this vaccine is a contraindication to administration of pentacel [see description (11) ]. encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including pentacel. progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy is a contraindication to administration of any pertussis-containing vaccine including pentacel. pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized. the safety and effectiveness of pentacel was established in the age group 6 weeks through 18 months on the basis of clinical studies [see clinical trials experience (6.1) and clinical studies (14) ]. the safety and effectiveness of pentacel in the age group 19 months through 4 years is supported by evidence in children 6 weeks through 18 months. the safety and effectiveness of pentacel in infants less than 6 weeks of age and in children 5 to 16 years of age have not been established.

Philippines - English - FDA (Food And Drug Administration)

hipra philippines, inc.; distributor: hipra philippines, inc. - escherichia coli fimbrial adhesins , e. coli lt enterotoxoid , clostridium perfringens b-toxoid , c. novyi type b a-toxoid vaccine (vet.) - suspension for injection (im) - each 2 ml (dose) contains: e. coli (f4ab fimbrial adhesin) e. coli (f4ac fimbrial adhesin) e. coli (f5 fimbrial adhesin) e. coli (f6 fimbrial adhesin) lt enterotoxoid of e.coli b-toxoid clostridium perfringens, type c á-toxoid clostridium novyi $5% er * »78% er70 59% er30 80% er25 5% er 70 5% ers >50% er 120

Philippines - English - FDA (Food And Drug Administration)

hipra philippines inc.; distributor: hipra philippines inc. - inactivated escherichia coli fimbrial adhesin (f4ab, f4ac, f5 and f6) , heat labile (lt) enterotoxoid , clotridium perfringens (type c) b toxoid , clostridium novyi (type b) a toxoid vaccine (vet.) - suspension for injection (im) - each 2 ml (dose) contains: escherichia coli fimbrial adhesin f4ab f4ac f5 f6 %65% er60 278% er70 279% er 50 >80% er35 >55% er 70 >35% er25 >50% er120 e. coli lt enterotoxoid clotridium perfringens (type c) btoxoid clostridium novyi (type b) a toxoid % erx: percentage of immunized rabbits with enzyme immunoassay response.

Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils.), inc. - inactivated escherichia coli fimbrial adhesin , heat labile toxoid (lt) vaccine (vet.) - suspension for injection (im) - formulation: each 2 ml (dose) contains: escherichia coli f4ab (k88ab) fimbrial adhesin (k12 strain) . escherichia coli f4ac (k88ac) fimbrial adhesin (k12 strain) escherichia coli f5 (k99) fimbrial adhesin (k12 strain) escherichia coli f6 (987p) fimbrial adhesin (987p-5 strain) escherichia coli lt toxoid (k12 strain) .. u – determinal antigenic mass by elisa (enzyme-lunkei immunosorbent assay) processed under fda memorandum circular 2021-001. ≥ 400 u 120 u ≥ 400 u ≥ 1000 u > 320 ng

Philippines - English - FDA (Food And Drug Administration)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - inactivated escherichia coli fimbrial adhesins , clostridium perfringens b-toxoid vaccine (vet.) - emulsion for injection (im) - formulation: each 2 ml (dose) contains: escherichia coli, f6 adhesins (p4 strain) ......... 21 rp f18ab adhesins (p5 strain) ....... 2 1 rp f4ac adhesins (p6 strain) 2 1 rp f18ac adhesins (p9 strain) .......... 2 1 rp f5 + f41 adhesins (p10 strain) .... 21 rp clostridium perfringens, type c, b-toxoid (czv13 strain) ............ 2 10 iu rp - relative potency iu - international unit (b-antitoxin per ml of rabbit serum)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Philippines - English - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation; distributor: broadchem philippines biopharma corporation - inactivated pasteurella multocida , bordetella bronchiseptica toxoid vaccine (vet.) - emulsion for injection (im) - formulation: each dose (2 ml) contains: pasteurella multocida (115/a strain)................10^10 - 10^11 cfu pasteurella multocida (type d dermonecrotoxic toxoid)....... 2-4 ug bordetella bronchiseptica (strain 6230)........... .......... 10^10 - 10^11 cfu cfu - colony forming unit

Namibia - English - Namibia Medicines Regulatory Council

serum institute of india ltd - adsorbed tetanus toxoid - injection - each single 0.5 ml human dose contains adsorbed tetanus toxoid ? 5 lf (? 40 iu)